DOSAGE INDEX / SINGLE
LL-37
Research, reported schedules and supply planning.
Read LL-37 wound-healing research in context: venous-ulcer and diabetic-foot trials, mixed outcomes, antimicrobial claims and FDA safety concerns.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 50–400 micrograms per day
- Frequency
- Once daily; optional five days weekly in the source
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Grönberg and colleagues reported an early randomized, placebo-controlled study involving 34 people with difficult-to-heal venous leg ulcers. It included a four-week blinded topical treatment phase. The indexed abstract reports favorable healing findings in the two lower-concentration groups. [2]
- The 2021 HEAL LL-37 trial randomized 148 patients with difficult-to-heal venous leg ulcers to topical LL-37 or placebo, alongside compression therapy. The full-population analysis did not identify a statistically significant improvement in healing. A post hoc analysis suggested benefit in participants with larger wounds, and the authors called for a further adequately powered study of that group. [3]
- Miranda and colleagues reported a randomized, double-blind study of LL-37 cream in diabetic foot ulcers with mild infection. Over four weeks, the LL-37 group had a greater increase in granulation index at the reported weekly assessments. The abstract did not show corresponding significant reductions in IL-1α, TNF-α or aerobic bacterial colonization. [4]
- FDA flags potential immunogenicity and characterization concerns for compounded LL-37 and insufficient information to determine human safety. It also notes nonclinical concerns involving male reproduction and tumor-promoting effects in some tissues. These are identified concerns, not a quantified prediction for every person. [5]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 13 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Zaiou et al., 2003: cathelicidin precursor and peptide research
- Grönberg et al., 2014: early venous-ulcer trial
- Mahlapuu et al., 2021: HEAL LL-37
- Miranda et al., 2023: diabetic-foot-ulcer cream trial
- FDA: bulk-substance safety concerns
- DiVA Portal / Wound Repair and RegenerationNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- Journal of Immunology (PMC)Further reading · Listed in reference bibliography.
- Innate Immunity (PMC)Further reading · Listed in reference bibliography.
- Wound Repair and Regeneration (PMC)Further reading · Listed in reference bibliography.
- Archives of Dermatological Research (PMC)Further reading · Listed in reference bibliography.
- CDC One & Only CampaignGeneral guidance · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- PubMed / Journal of Steroid BiochemistryFurther reading · Listed in reference bibliography.
- MedlinePlus (NIH)General guidance · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Clinical Pharmacology & Therapeutics (PMC)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.